Opinion|Videos|August 5, 2024
Financial Challenges of BTK Inhibitor Therapy in CLL: Impact on Access and Utilization
Experts discuss financial challenges of BTK inhibitor therapy.
Advertisement
Episodes in this series
Video content above is prompted by the following question(s):
- What are the financial burdens of BTK inhibitor therapy? How does the cost of BTK inhibitors impact access and utilization for patients with CLL?
Advertisement
Related to this article
Using baseline samples from 177 patients in the VISION/HO141 trial, researchers built a functional prognostic model for CLL that outperformed the CLL-IPI.
Advertisement
Advertisement
Trending on AJMC
1
Pathological Response Does Not Reliably Predict Survival in Sarcoma
2
New CHEST Guidelines Offer a Road Map for Bronchiectasis
3
CHEST Investigations Explore COPD Guideline Adherence, Adding Ensifentrine, and Use of AI in Education
4
CHEST Highlights Practice-Changing COPD Therapy and Strategies
5